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Abstract Attention-deficit hyperactivity disorder (ADHD) is
a developmental disorder characterized by symptoms of inat-
tention, impulsivity and hyperactivity that adversely affect
many aspects of life. Whereas the etiology of ADHD remains
unknown, growing evidence indicates a genetic involvement
in the development of this disorder. The brain circuits associ-
ated with ADHD are rich in monoamines, which are involved
in the mechanism of action of psychostimulants and other
medications used to treat this disorder. Dopamine (DA) is
believed to play a major role in ADHD but other neurotrans-
mitters are certainly also involved. Genetically modified mice
have become an indispensable tool used to analyze the con-
tribution of genetic factors in the pathogenesis of human
disorders. Although rodent models cannot fully recapitulate
complex human psychiatric disorders such as ADHD, trans-
genic mice offer an opportunity to directly investigate in vivo
the specific roles of novel candidate genes identified in
ADHD patients. Several knock-out and transgenic mouse
models have been proposed as ADHD models, mostly based
on targeting genes involved in DA transmission, including the
gene encoding the dopamine transporter (DAT1). These mu-
tant models provided an opportunity to evaluate the contribu-
tion of dopamine-related processes to brain pathology, to
dissect the neuronal circuitry and molecular mechanisms in-
volved in the antihyperkinetic action of psychostimulants and
to evaluate novel treatments for ADHD. New transgenic
models mouse models targeting other genes have recently
been proposed for ADHD. Here, we discuss the recent
advances and pitfalls in modeling ADHD endophenotypes in
genetically altered animals.
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Attention deficit hyperactive disorder (ADHD) is a clinically
heterogeneous disorder presenting as various combinations of
impulsivity, hyperactivity and inattention symptoms. ADHD is
among the most common neuropsychiatric disorders in chil-
dren, affecting 5%–7% of children worldwide (Polanczyk et al.
2007; Faraone et al. 2003; Faraone and Mick 2010; Willcutt
2012) and often leads to adverse consequences in adult life
including drug abuse, delinquency, anxiety and depression and
social rejection (Barkley et al. 2004; Biederman 2005; Bernardi
et al. 2012). ADHD creates a significant financial burden
involving the cost of medical care and work loss for patients
and family members. Causative mechanisms for ADHD have
not yet been identified and at present, no objective biomarkers
are available to support the diagnosis, which is based on
symptom descriptions in the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition (DSM-IV)
(American Psychiatric Association 2000). However, a diversity
of ADHD clinical forms might result in a revision of the
diagnosis, classification and segregation of the distinct nosol-
ogies of ADHD in a new DSM-Vedition.
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Although the exact molecular mechanisms involved in
the etiology of ADHD have yet to be uncovered, clinical
studies clearly indicate that ADHD has a significant genetic
component (Lasky-Su et al. 2007; Faraone et al. 2005; Purper-
Ouakil et al. 2011), most likely involving several genes with
each determining the severity of particular symptoms.
Environmental components that have been implicated as risk
factors include brain traumas during infancy and alcohol or
drug abuse during pregnancy (Sinopoli et al. 2011; Mick et al.
2002a, b; Biederman et al. 1995). Thus, genetic, developmental
and environmental factors influence the severity of symptoms
observed in affected individuals, leading to a “spectrum” of
abnormal behaviors (Dick et al. 2010). Nevertheless, some
ADHD patients present some brain abnormalities (e.g., a re-
duction in total brain volume; Valera et al. 2007), especially in
the basal ganglia, prefrontal cortex and cerebellum (Giedd et al.
2001; Cortese and Castellanos 2012) and alterations in neural
networks (Rubia et al. 2010; Konrad and Eickhoff 2010).
The circuits associated with ADHD are rich in monoamines,
which are involved in the mechanism of action of the
psychostimulants and antidepressants used to treat this disor-
der. Neuropharmacological studies provide evidence that
ADHD involves the dysregulation of complex interactions
between the dopamine (DA), norepinephrine (NE) and 5-
hydroxytryptamine (serotonin) neurotransmitter systems
(Pliszka 2005; Himelstein et al. 2000; Heal et al. 2009). For
more than 70 years, ADHD treatment has been dominated by
the use of monoaminergic psychostimulants (Bradley 1937),
mostly methylphenidate (MPH) and amphetamine (AMPH),
plus the catecholaminergic nonstimulant atomoxetine (ATX).
These medications are generally believed to exert their thera-
peutic effects by increasing the availability of monoamines in
the synapse by reducing their uptake rates or promoting re-
verse efflux as a result of interactions with monoamine trans-
porters on the plasma membrane. Notably, not all patients
respond to these treatments and both responders and non-
responders to amphetamine and methylphenidate therapy in
the clinic have been documented (Heal et al. 2009; Krause et
al. 2005).
The involvement of monoamines in ADHD is also
supported by candidate gene association studies that show
positive associations with various DA (dopamine receptor 4,
DR4; dopamine receptor 5, DR5; dopamine transporter, DAT;
Faraone et al. 2005; Li et al. 2006; Gizer et al. 2009; Brookes et
al. 2006), NE (norepinephrine transporter, NET; Yang et al.
2004; Kim et al. 2008) and serotonergic (serotonin transporter,
SERT; serotonin receptor subtype 1B gene, HTR1B; Faraone
andKhan 2006) genes. However, monoamines in general act as
modulators of fast neurotransmission mediated by glutamate
and gamma aminobutyric acid (GABA) suggesting that many
other mechanisms beyond those involved exclusively in mono-
aminergic transmission could be important for the pathogenesis
of ADHD and the targeting of these mechanisms could provide
more specific pharmacological and cognitive therapies for this
disorder (Carlsson et al. 2001; Greengard 2001; Gainetdinov et
al. 2001). These findings suggest that ADHD is likely to be
based on several specific neurobiological dysfunctions and
involves many genes, each with small effect sizes (Faraone et
al. 2005).
Some specific endophenotypes of ADHD can be relatively
easily modeled by targeted genetic manipulations in experi-
mental animals, as is in the case with other neuropsychiatric
disorders with a significant genetic component. An idealmodel
needs to recapitulate all the key endophenotypes of ADHD:
inattention, impulsivity and hyperactivity. However, one single
model is unlikely to be able to mimic all ADHD symptoms. At
the same time, a model that recapitulates some key
endophenotypes of the disorder could be useful for understand-
ing the biological basis of the particular aspects of the disease
and for predicting the clinical efficacy of potential therapeutic
agents in specific clinical forms of the disorder. Thus, an
ADHD animal model should mimic the fundamental behav-
ioral characteristics of ADHD (face validity), involve a similar
etiology and/or underlying pathophysiological mechanism
(construct validity) and predict responses to medications that
could be used in ADHD treatment with regard to behavior,
molecular mechanisms and neuronal functions that have not
previously been shown in clinical settings (predictive validity;
Sagvolden and Johansen 2012; Gainetdinov 2010). Whereas
nonhuman primate brains are closer to human brains, rodent
models of ADHD have the advantage of being genetically
more homogeneous, less expensive to maintain and more
thoroughly characterized neurobiologically in comparison
with primates (Russell et al. 2005). Thus, mouse models are
invaluable tools for directly testing hypotheses on the under-
lying pathologies and finding new pharmacological therapies
for human disorders in a relatively short period of time.
Because ADHD is a heterogeneous disorder, a number of
animal models have unsurprisingly been proposed that mimic
symptoms of ADHD. Here, we review only transgenic rodent
models with defined genetic causes that have been proposed to
be useful tools for understanding ADHD neurobiology
(Table 1). We do not discuss rodent models with unknown
genetic origins or those that are based on environmental in-
terventions or chemical lesions, such as the inbred spontane-
ously hypertensive rat (SHR), the Naples high-excitability rat
(NHE), or neonatal 6-hydroxydopamine (6-OHDA) lesioned
mice, which are by far the most widely studied rodent models
of ADHD and subjects of a number of excellent reviews
(Russell 2011; Sagvolden et al. 2009; Bari and Robbins 2011).
Transgenic models: dopamine transmission-related genes
The widespread use of rodents, especially mice, in preclin-
ical research has been steadily growing since the
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development of transgenic knock-out techniques in the 1980s
(Smithies 1993) and the publication of the mouse genome in
2002 (Mouse Genome Sequencing Consortium et al. 2002).
Rodents provide relatively easy targets for genome manipula-
tion in order to create disease models by targeting candidate
genes and by analyzing the related dysfunctions on a con-
trolled genetic background. Use of the candidate ADHD gene
approach in a recent meta-analysis of studies performed over
the past 15 years has revealed consistent evidence of signifi-
cant associations between ADHD and polymorphisms in sev-
eral candidate genes, almost all of which are involved in the
regulation of dopaminergic and serotonergic transmission
(Gizer et al. 2009; Wu et al. 2012). The generation of
knock-out, knock-in, or transgenic over-expressing animals
has become a novel approach to investigating the neu-
ronal and biochemical basis of ADHD. These transgenic
mouse models representing bottom-up approaches (from
gene to behavior) have provided an opportunity to link
a specific gene to specific endophenotypes of the disease,
thus complementing alternative top-down approaches (i.e.,
from behavior to the genes) based, for instance, on the selec-
tive breeding of animals demonstrating ADHD-related behav-
ioral phenotypes of unknown origin (Russell 2011; Sagvolden
et al. 2009; Bari and Robbins 2011).
Like all rodent models, transgenic mice certainly have
some limitations. First, given that ADHD appears to be a
complex and multifactorial disease with no reliable genetic
or biochemical markers, such mouse mutants can obviously
have only limited construct validity. Moreover, the deletion
of certain genes might produce different phenotypes in
humans and animals and transgenic animal models might
not be powerful enough to mimic gene epistasis, effects of
“small mutations”, adaptive functional compensation and
abnormal neuronal system development. Nevertheless,
transgenic animals are the most reliable and simple models
used to study gene-function relationships and to investigate
the effects of novel pharmacological approaches.
DAT knock-out mice
Several lines of evidence suggest that abnormal DAT func-
tion is important in ADHD. Both increased and decreased
DAT expression have been reported in small cohorts of
ADHD patients (Sakrikar et al. 2012; Madras et al. 2005;
Volkow et al. 2002) and genetic studies have demonstrated
the associations of DAT gene variants with unknown func-
tional consequences with ADHD (Spencer et al. 2012). A
link between DAT function and ADHD is further suggested
by the therapeutic utility of the psychostimulants methyl-
phenidate (Ritalin) and AMPH, which exert a significant
part of their action via an interaction with DAT (Sakrikar et
al. 2012). Thus, several transgenic animal models of ADHD
have been developed based on the postulated role of DA,
particularly DAT, in this disorder.
Table 1 Mutant mice with relevance to ADHD discussed in this review
Mutant mice Mutation References
Dopamine transmission-related genes
• DAT-KO Knock-out of dopamine transporter gene Giros et al. 1996; Gainetdinov and Caron
2000; Trinh et al. 2003
• DAT-KD Knock-down of dopamine transporter gene Zhuang et al. 2001; Tilley et al. 2007
• DAT-CI Triple point-mutation in the cocaine-binding site of DAT Napolitano et al. 2010; Tilley and Gu 2008a
• BAC DAT-tg Overexpression of dopamine transporter Salahpour et al. 2008
• D4R-KO Knock-out of dopamine receptor 4 Rubinstein et al. 1997; Helms et al. 2008
Other genes
• NK1R-KO Knock-out of tachykinin-1 receptor De Felipe et al. 1998; Yan et al. 2009
• TRβPV-KI Knock-in of human thyroid hormone β receptor gene Kaneshige et al. 2000; Siesser et al. 2006
• 39 XyO mice End-to-end fusion of the X and Y chromosome
resulting in steroid sulfatase deficiency
Davies et al. 2007, 2009
• Coloboma mice/SNAP25
(synaptosomal-associated
protein 25) mutant mice
Mutation on chromosome 2 with approximately
20 genes disrupted including SNAP-25
Searle 1966; Bruno et al. 2007
• nAChR β2-KO Knock-out of β2-subunit of the nicotinic
acetylcholine receptor
Granon et al. 2003; Granon and Changeux 2006
• CK1δ mice Over-expression of the subunit δ of casein kinase1 Zhou et al. 2010
• Git1-KO Knock-out of G-protein-coupled receptor
kinase-interacting protein-1
Won et al. 2011; Schmalzigaug et al. 2009
• CdK5-KO Knock-out of Cdk5-activating cofactor p35 Drerup et al. 2010
• Gβ5-KO Knock-out of type 5 G protein beta subunit Xie et al. 2012
• DGKβ KO Knock-out of diacylglycerol kinase β Ishisaka et al. 2012
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DAT is a member of the family of Na+/Cl−-dependent
transporters that have the general structure of 12 transmem-
brane domains with intracytoplasmic carboxy- and amino-
terminals (Giros and Caron 1993; Kristensen et al. 2011;
Torres et al. 2003). The DAT protein is expressed selectively
in DA cell bodies and terminals and can be used as a
selective marker of DA neurons (Eriksen et al. 2010). In
the central nervous system, DAT is mainly expressed in the
striatum and nucleus accumbens, whereas in the periphery, it
is present in the retina, lung, kidney and pancreas (Ciliax et
al. 1995). In the striatum, DAT is exclusively presynaptic
and is localized to the plasma membranes of axonal vari-
cosities and axon terminals (Nirenberg et al. 1996). The
major function of DAT is the reuptake of DA from the
synaptic cleft into presynaptic nerve terminals, making
DAT essential in controlling the half-life of extracellular
DA. The psychostimulatory actions of MPH, cocaine and
AMPH are primarily dependent on a direct interaction of
these compounds with DAT, leading to attenuated DA clear-
ance and thus elevated DA tone (Chen et al. 2006; Pifl et al.
1996; Thomsen et al. 2009; Fumagalli et al. 1998). These
drugs generally exert inhibitory and/or specific reversing
actions on the function of the monoamine transporters
DAT, NET and SERT, thereby disrupting the normal reup-
take of neurotransmitters from the synaptic cleft and causing
an elevation in the extracellular monoamine levels.
Although the debate continues as to whether ADHD is a
hypo- or hyper-dopaminergic condition, numerous clinical
genetic studies have provided evidence that alterations in
DAT-mediated processes significantly contribute to the
pathogenesis of ADHD (Gainetdinov 2010). DAT knock-
out mice (Giros et al. 1996; DAT-KO mice) have provided
important information concerning the neurobiological con-
sequences of impaired DAT function. DAT-KO mice are
considered ADHD models for many reasons, including their
spontaneous hyperactivity and impaired learning and mem-
ory (Gainetdinov and Caron 2000, 2001; Trinh et al. 2003).
Recent studies have also demonstrated an impaired cliff-
avoidance reaction in DAT-KO mice, indicating increased
impulsivity in these mutants (Yamashita et al. 2013). Unlike
wild-type or heterozygous mice, DAT-KO mice are signifi-
cantly more active in novel and home-cage environments
and show remarkable deficits in learning and memory in the
8-arm maze, novel object recognition and social food pref-
erence transmission tests (Gainetdinov et al. 1999a; Wong et
al. 2012). In DAT-KO animals, DA clearance is approxi-
mately 300 times slower than in controls (Gainetdinov et al.
1999b; Jones et al. 1998, 1999). However, the increase in
the basal extracellular levels of DA is only approximately
five-fold (two-fold in the DAT heterozygous mice), because
of several compensatory mechanisms (Gainetdinov and
Caron 2000, 2001; Trinh et al. 2003). Intriguingly, electri-
cally stimulated DA release is reduced and a marked
depletion of reuptake-dependent intraneuronal DA stores
(20-fold) is observed in these mutants (Gainetdinov et al.
1999b; Jones et al. 1998). Thus, we can speculate that the
steady-state “tonic” extracellular DA levels are increased
but that “phasic” DA release might, in fact, be diminished
because of depleted storage pools (Gainetdinov 2010).
Importantly, the lack of DAT-mediated recycling makes
DA levels in the striatum of these mice totally dependent
on the rate of the ongoing synthesis of DA (Jones et al.
1998; Sotnikova et al. 2005). Notably, DAT-KO mice have
disrupted DA autoreceptor function and significantly re-
duced tyrosine hydroxylase (TH) protein expression, despite
only minor alterations in the number of TH-positive neurons
(Giros et al. 1996; Jaber et al. 1999). Indeed, unlike the
normal situation in which the predominant mode of DA
transmission in the striatum can be defined as a point-to-
point wired transmission, this mode in DAT-KO mice can be
defined as “volume transmission” in which released mole-
cules can diffuse over longer distances in the extracellular
space, thus affecting larger volumes of postsynaptic recep-
tors and structures (Jones et al. 1998). Volume transmission
is believed to occur in situations in which DAT-mediated
DA reuptake is low, as in the frontal cortex or following
dopaminergic degeneration in the striatum; this causes a
reduction in the number of DA terminals and re-uptake sites
(Zoli et al. 1999). Similar situations might occur in another
commonly used model of ADHD, i.e., neonatal 6-
hydroxydopamine (6-OHDA)-treated rodents. In this neuro-
toxic ADHD model, which is used to support the
hypodopaminergic theory of this disorder, the neonatal ad-
ministration of the neurotoxin 6-OHDA exerts selective
dopaminergic neurotoxicity by entering terminals via DAT
that causes transient hyperactivity and cognitive deficits that
last approximately 2 weeks in 40%–50% of the animals
(Kostrzewa et al. 2008). Because DAT function in rodents
is relatively low in the early neonatal period (Gordon et al.
1995; Patel et al. 1994), one might expect that only neurons
with sufficient DAT function would be affected by 6-
OHDA, leaving neurons with delayed maturation of DAT
intact and thus causing a transient state of low DAT-
mediated re-uptake and “volume transmission”.
As in ADHD patients, MPH and AMPH are able to
reduce hyperactivity in DAT-KO animals (Gainetdinov et
al. 1999a). Therefore, these mice have face and predictive
validity as a model of ADHD. The “calming” effect of
psychostimulants suggests the involvement of a DAT-
independent mechanism of action, possibly involving other
monoamine transporters. The administration of inhibitors of
the serotonin transporter (SERT) or of several serotonin
receptor agonists and antagonists (non-selective agonists
quipazine and 5-carboxamidotryptamine or the selective
5HT2A antagonist M10090) dramatically reduces the hy-
peractivity in DAT-KO mice (Gainetdinov et al. 1999a; Barr
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et al. 2004; Beaulieu et al. 2006) indicating an involvement
of serotonergic mechanisms. At the same time, the specific
NET inhibitor nisoxetine does not suppress the hyperactivity
of DAT-KO animals (Gainetdinov et al. 1999a; Gainetdinov
and Caron 2000) but reverses the manifestations of impul-
sivity in the cliff-avoidance test (Yamashita et al. 2013) and
sensorimotor gating deficits in the pre-pulse inhibition test
(Arime et al. 2012). The involvement of both SERT- and
NET-mediated effects of psychostimulants in these models
is not surprising because both SERT-KO and NET-KO mice
are hypoactive (Kalueff et al. 2007; Xu et al. 2000) and, as is
well established, the serotonin and NE systems closely
interact at many levels, with alterations in one neurotrans-
mitter system causing significant changes in the other
(Bortolozzi and Artigas 2003).
Glutamatergic transmission might also be an intermediate
in the inhibitory action of psychostimulants and serotonergic
drugs on the hyperactivity of DAT-KO mice. The blockade of
N-methyl-D-aspartate (NMDA) receptors causes a remarkable
potentiation of hyperactivity in DAT-KO mice and prevents
the antihyperkinetic effects of psychostimulants and seroto-
nergic drugs suggesting the involvement of cortico-striatal
glutamatergic pathways in the effects of these drugs.
Importantly, whereas the psychomotor stimulatory effect of
psychostimulants is correlated with the well-known rise in
extracellular DA levels in major DA brain areas in normal
mice, psychostimulants inhibit activity without causing a de-
crease in elevated DA levels in DAT-KOmice. These findings
give further support to the idea that, in these mutants,
psychostimulants do not affect the striatal DA system directly
but instead exert their antihyperkinetic effects by modulating
different neurotransmitter systems in other brain regions
(Gainetdinov et al. 1999a). These observations particularly
highlight the processes occurring in the frontal cortex in
regulating striatal mechanisms. In general, DA transmission
in the striatum and frontal cortex might be differentially in-
volved in the control of certain behaviors, with striatal mech-
anisms mostly contributing to the regulation of locomotor
activity and cortical mechanisms regulating predominantly
cognitive processes such as attention and impulsivity.
Whereas extracellular DA levels in the frontal cortex of
DAT-KO mice are elevated as in the striatum (Xu et al.
2009), NET is known also to contribute to the clearance of
DA in this brain region. Thus, either the modulation of cortical
DA dynamics via NET inhibition or the direct serotonin-
mediated modulation of the frontostriatal glutamatergic path-
way might potently affect the aberrant behaviors caused by an
enhanced striatal DA transmission in these mutants.
In summary, this mouse model shows face and predictive
validity because of behavioral similarities, alterations in the
catecholaminergic system and the effectiveness of
psychostimulants. However, since no clear indications are
yet available that the DAT level or function is altered in
patients with ADHD, the construct validity of DAT-KO is
only partial. Human studies on the role of DAT in ADHD
etiology are still controversial, although recent brain imaging
studies have shown a decrease in DAT levels in several brain
areas of ADHD patients (Volkow et al. 2007, 2009a).
Intriguingly, recent studies have found two novel DAT-
coding variants: A559V, which has been identified in two
male siblings with ADHD displaying increased DAT channel
activity and spontaneous non-vesicular DA release that can be
greatly enhanced by membrane depolarization (Mazei-
Robison et al. 2008; Bowton et al. 2010) and a second rare
ADHD-associated DAT-coding variant, R615C, in which
amino acid substitution results in significant regulatory alter-
ations in DAT function (Sakrikar et al. 2012).
Other DAT mutant models
Another model of mild DAT deficiency has been developed
by the local injection of small interfering RNA (siRNA)
against DAT into the midbrain of adult mice (Salahpour et
al. 2007). However, despite a decrease of approximately 40%
in DAT levels, no alterations in spontaneous locomotor activ-
ity have been found. At the same time, decreased levels of
DAT have been functionally revealed by the lower level of
hyperactivity induced by AMPH in siRNA-treated animals
(Salahpour et al. 2007). Whereas these DAT siRNA-treated
mice and DAT heterozygous mice displaying a 50% reduction
in DAT levels do not show phenotypes that are relevant to
ADHD, mice with more severe DAT functional deficits, e.g.,
DAT knock-down mice (DAT-KD) and DAT cocaine-
insensitive (DAT-CI) mice, represent useful models for under-
standing the role of DAT in ADHD. Hyperdopaminergic
DAT-KD mice were created by reducing the expression of
DAT to 10% of wild-type levels (Zhuang et al. 2001). Similar
to DAT-KOmice, DAT-KDmice display a reduced rate of DA
reuptake and a higher extracellular DA concentration (approx-
imately two-fold higher than controls). DAT-KD mice display
normal home cage activity but significant hyperactivity and
impaired response habituation in novel environments. These
mutants also demonstrate an increased motivation for food
reward but do not show significant alterations in learning
abilities. Notably, as in DAT-KO mice, AMPH exerts a pro-
nounced inhibitory effect on locomotor activity in the DAT-
KD mouse; in contrast, the normal stimulatory effects of
cocaine have been reported (Tilley et al. 2007).
An additional strain of DAT-deficient mice, i.e., DAT-CI
(Cocaine Insensitive) mice, were obtained by introducing a
triple point-mutation in the cocaine-binding site of DAT
(Napolitano et al. 2010; Chen et al. 2006). In these animals,
DAT is partially functional but insensitive to cocaine. Because
of their significantly reduced DAT function (estimated to be in
the range of 60%–80%, based on a comparative analysis of
various neurochemical parameters), DAT-CI mice exhibit
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severe alterations of DA signaling in the striatum, such as
elevated extracellular DA levels, decreased total striatal DA
content, enhanced DA turnover and reduced D2 dopamine
receptor-mediated autoreceptor function (Napolitano et al.
2010). DAT-CI mice also lack cocaine-induced extracellular
DA elevation and cocaine- and MPH-induced conditioned
place preference (Tilley and Gu 2008a, b). As might be
expected, DAT-CI mutants display significant spontaneous hy-
peractivity (Napolitano et al. 2010). Whereas the cognitive
phenotype of these mutants has not yet been characterized,
not only cocaine but also several other psychostimulants, in-
cluding AMPH, MPH, nomifensine and bupropion, exert
antihyperkinetic action in DAT-CI mice (Napolitano et al.
2010). Similarly, a NET inhibitor has been able to induce a
moderate decrease in the activity of these hyperdopaminergic
mutants (Napolitano et al. 2010). Taken together, the observa-
tions of DAT-KD and DAT-CI mice support the major findings
observed in DAT-KO mice. However, neither DAT-KD nor
DAT-CI mice show all of the cardinal phenotypes of an
ADHD mouse model, thereby displaying only partial face
validity. Conversely, several attempts have been made to eval-
uate the effects of increased DATexpression in animal models.
Although many of the DAT-deficient mice described above
have phenotypes that are at least partially relevant for ADHD,
the behaviors displayed by mice with increased DAT expres-
sion lack such validity. The transgenic over-expression of DAT
in TH-expressing neurons by approximately 30% results in
spontaneous locomotor hypoactivity in a new environment
(Donovan et al. 1999). Adriani et al. (2009) have used a
lentivirus to over-express or silence the DAT gene by infusing
a DAT gene enhancer/silencer into the nucleus accumbens of
adult Wistar rats. In the absence of general locomotor effects,
DAT over-expressing rats show a somewhat increased impul-
sivity but they do not demonstrate a significant preference for a
novel environment. The authors suggested that altered
accumbal DAT function might serve a sensation-seeking phe-
notype and a vulnerability to impulse-control disorders.
Salahpour and colleagues (2008) have generated, via the pro-
nuclear injection of a bacterial artificial chromosome, DAT
transgenic mice (DAT-tg) that significantly overexpress the
transporter. In DAT-tg mice, a three-fold increase in the level
of total transporter has been achieved, which results in a 50%
increase in the rate of DA uptake and a 40% decrease in DA
extracellular levels. Behaviorally, these mice display normal
levels of spontaneous locomotor activity but markedly in-
creased locomotor responses to AMPH and reduced operant
responses to a natural reward. These studies indicate that in-
creased DAT expression does not recapitulate the major
endophenotypes related to ADHD (no face or predictive valid-
ity), such as hyperactivity and the paradoxical inhibitory re-
sponses to AMPH (Salahpour et al. 2008). In contrast, the
behavioral phenotype and the responses to psychostimulants
in various strains of DAT-deficient mice generally support the
clinical observations of decreased (Volkow et al. 2009b, 2007),
rather than increased (Madras et al. 2005) DAT expression
found in some ADHD patients, although these alterations
might represent secondary adaptive changes but not causative
factors of the disease. Intriguingly, DAT expression and func-
tion in normal rodents has been found to be relatively low at
birth, with significant maturation of DAT occurring over an
extended period of postnatal development (Gordon et al. 1995;
Patel et al. 1994). If a similar developmental maturation of DAT
occurs in humans, the relatively low DAT function during
childhood could explain the preferential appearance of
ADHD in children. Furthermore, one might expect that defi-
ciencies in processes that are critical for DAT maturation will
contribute to the etiology of this developmental disorder.
D4 dopamine receptor KO mice
Mice lacking the D1, D2, D3, D4 and D5 receptors, or some
combination thereof, have been produced but all have failed to
showADHD-related phenotypes. Among all DA receptors, the
most studied receptor has been D4R. Whereas alleles of the
humanD4Rgene have repeatedly been associatedwith ADHD
(Grady et al. 2003), D4R knock-out (D4R-KO; Rubinstein et
al. 1997) mice have failed to become a valid ADHD model.
These mutants demonstrate hypoactivity and have similar
levels of impulsivity compared with control animals,
suggesting that D4R-mediated signaling does not affect impul-
sivity (Helms et al. 2008). At the same time, D4R-KOmice are
supersensitive to alcohol, cocaine and methamphetamine. DA
synthesis and its conversion to DOPAC are elevated in the
dorsal striatum of D4R-KO mice (Rubinstein et al. 1997).
Taken together, these observations provide little support to
consider D4R-KO mice a relevant model in ADHD research.
Transgenic models: other genes
Tachykinin-1 (NK1) receptor
The tachykinin-1 (NK1) receptor is a receptor for substance
P, which is a member of the tackyinin family of neuropep-
tides (Maggi 1995). Substance P levels are high in mono-
aminergic nuclei, especially in the substantia nigra and
ventral tegmental area (Ljungdahl et al. 1978; Ribeiro-da-
Silva and Hökfelt 2000). Substance P preferentially acti-
vates NK1 receptors (NK1R), which are the product of the
tacr1 gene. Another subtype of substance P receptor, NK2,
has lower binding affinity than NK1R and has only limited
expression in the rat or human brain (McLean and Lowe
1994). NK1R is a member of the family of G protein-coupled
receptors and is mainly expressed in subcortical regions (i.e.,
amygdala/hippocampus and striatum; Yan et al. 2009). When
NK1R-KO animals were generated in 1998 (De Felipe et al.
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1998), the discovery of an important modulatory influence of
tachykinin-1 (now known as TACR1 in humans or NK1R in
rodents) on monoaminergic transmission attracted interest
with regard to this factor being a novel target for antidepres-
sants (Yan et al. 2009). In NK1R-KO mice, the serotonergic
(Froger et al. 2001), norepinephrinergic (Fisher et al. 2007;
Herpfer et al. 2005) and dopaminergic systems are affected
(Murtra et al. 2000). The serendipitous discovery that NK1R-
KO mice express core features of ADHD arose from the
observation that NK1R-KO mice express minor locomotor
hyperactivity corrected by psychostimulants (AMPH or
MPH). Moreover, hyperactivity is induced in wild-type mice
by treating them with an NK1R antagonist at doses that have
no effect on the behavior of NK1R-KO mice; this hyperactiv-
ity is prevented by AMPH, as occurs in NK1R-KO mice (Yan
et al. 2009). These mutants also display other abnormalities
that might be relevant to ADHD, such as reduced DA efflux in
the frontal cortex, a lack of an increase in DA efflux in the
dorsal striatum following systemic administration of AMPH
and a lack of development of AMPH or morphine-induced
conditioned place preference (Yan et al. 2009, 2010). NK1R-
KO mice have been reported to express inattentiveness and
impulsivity in five-choice serial reaction-time task tests (5-
CSRTT) but AMPH does not correct these deficits (Yan et al.
2011). In a case–control study of 450 ADHD patients and 600
screened normal controls, four single-nucleotide polymor-
phisms at the TACR1 gene, previously known to be associated
with bipolar disorder or alcoholism, were strongly associated
with ADHD (Yan et al. 2010). Thus, NK1R-KO animals
display some face and predictive validity as a model of
ADHD and, with further validation, might become an inter-
esting new model of the disease.
Thyroid hormone receptor
Resistance to the thyroid hormone (RTH) has long been
known to be often associated with symptoms of hyperactiv-
ity (Hauser et al. 1993; Magner et al. 1986). RTH is linked
to mutations in exons 9 and 10 of the human thyroid hor-
mone β receptor gene (TRβ). It is characterized by a normal
or elevated level of the thyroid-stimulating hormone (TSH)
in the presence of high levels of serum triiodothyronine (T3)
and thyroxine (T4) and by the resistance of pituitary or
peripheral tissues to the actions of the thyroid hormone
attributable to a decreased affinity of TRβ for T3
(McDonald et al. 1998). In two studies, 50%–70% of RTH
patients met the diagnostic criteria for ADHD (Hauser et al.
1993; Brucker-Davis et al. 1995) supporting the idea that
this gene might be involved in ADHD pathogenesis. A
model of knock-out mice lacking the TRβ gene was gener-
ated by Forrest and colleagues (1996). These animals had
elevated TSH and free T3 and T4 but they were not hyper-
active. However, male transgenic mice bearing the human
PV (the acronym for the patient name) mutant TRβ gene
(RTH mutants) tested for horizontal activity displayed some
hyperactivity and a moderate deficit in learning, showing
normal performance after training for a reaction time task
that measured sustained attention (McDonald et al. 1998).
The TRβPV knock-in (KI) mice seemed to be more prom-
ising as a model of ADHD (Kaneshige et al. 2000), as they
displayed the characteristic endophenotypes of ADHD: in-
attention manifesting as slow reaction times and inaccuracy
in an operant task, moderate hyperactivity that was not
evident in a novel environment but developed gradually after
repeated exposure to the environment and impulsivity
observed by indirect measures (Siesser et al. 2005, 2006).
TRβPV-KI mice show increased striatal DA turnover but the
response to MPH does not differ between genders or between
transgenic and wild-type animals; an initial transient decrease
of activity is followed by normalization up to baseline values
within 1 h (Siesser et al. 2006). Hence, these mice seem to
have some face validity as an ADHD model but limited
construct validity. Ambiguous face and predictive validity
(the ambiguous response to MPH) detract from the validity
of this model, as demonstrated by the absence of recent reports
concerning TRβPV-KI mice utility to model ADHD.
Steroid sulfatase
Steroid sulfatase (STS) is an enzyme encoded by the X-
linked gene STS (Xp22.3) in humans and by the
pseudoautosomal Sts gene in mice. It catalyzes the
desulfation of steroid hormones, such as the neurosteroid
dehydroepiandrosterone sulfate (DHEAS) to DHEA.
DHEAS and DHEA have important effects on neuronal
functions, including cognition, by acting on various neuro-
transmitter receptors (GABA-A, NMDA; Davies et al. 2009;
Reddy 2010). Both DHEAS and its non-sulfated form
DHEA are negative modulators of the GABA-A receptor
and positive modulators of the NMDA receptor (Yadid et al.
2010). STS is expressed in key regions of the developing
brain critical for attention and impulsivity, including the
frontal cortex, thalamus and basal ganglia, i.e., regions
whose structure/function is expected to be perturbed in
ADHD (Stergiakouli et al. 2011). Several lines of evidence
have suggested a role of STS in ADHD: males with cytoge-
netic deletions encompassing the gene (or with inactivating
mutations within it) show an enhanced vulnerability to the
disorder (Brookes et al. 2010; Kent et al. 2008). DHEA(S)
levels are inversely correlated with ADHD symptomatology
(Strous et al. 2001) and can be elevated by MPH treatment
(Maayan et al. 2003; Lee et al. 2008). Moreover, the total or
partial loss of the X chromosome in Turner syndrome results
in attention deficits. In 1997, Davies and colleagues
reported that, in 39 XyO mice with an end-to-end fusion of
the X and Y chromosome, haploinsufficiency for STS
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accounted for attentional deficits (see Davies et al. 2009,
2007) by limiting the conversion of DHEAS to DHEA.
Furthermore, DHEAS administration improved the atten-
tional deficits in 39 XyO mice, suggesting that STS deletion
is a possible model for the inattentive subtype of ADHD.
Further characterizations of this mouse model have shown
similarities with ADHD endophenotypes such as hyperac-
tivity, heightened emotional reactivity and aggression and
lowered serum DHEA levels (Trent et al. 2012a, b). The
authors propose that these deficits are related to increased
tissue serotonin levels in the striatum and hippocampus as a
result of reduced DHEA levels (Trent et al. 2012a). The
putative role of the STS gene in ADHD is also supported by
the results of the pharmacological blockade of the activity of
the enzyme in normal animals. This treatment produces
visuo-spatial attentional deficits, perseverations, aggression
and increased locomotor activity comparable with those
observed in 39 XyO mice. Thus, 39 XyO mice have partial
construct validity as an ADHD model and exhibit a reason-
able degree of face validity. However, as with other “new”
ADHD models, further investigations are needed to under-
stand the neurobiological underpinnings of the behavioral
endophenotypes caused by this mutation.
Other mutant mice that are relevant for ADHD
In 1966, a mutant mouse strain resulting from neutron irradi-
ation, the coloboma mutant mouse, was described (Searle
1966). These mutants bear a mutation on chromosome 2 with
approximately 20 genes being disrupted (e.g., PCLB-1 [phos-
pholipase c beta-1] and Jag1 [Jagged 1]). Among these genes,
the synaptosomal-associated protein 25 (SNAP-25), which is a
key protein in synaptic vesicle docking and fusion with the
presynaptic membrane, has attracted the most interest. These
mice display delayed neurodevelopment and behavioral defi-
cits that might recapitulate to some degree the developmental
deficits in ADHD patients. The mice exhibit pronounced hy-
peractivity, impulsivity and impaired inhibition in a delayed
reinforcement task (Bruno et al. 2007;Wilson 2000; Hess et al.
1994, 1996). Coloboma mice also have disrupted latent inhi-
bition, thus indicating “inattentive” behavior (Bruno et al.
2007). The hyperkinetic behavior is corrected to a certain
extent by AMPH but not at all by MPH (Hess et al. 1996;
Wilson 2000) and so the mice respond only partially to classi-
cal ADHD treatments. Catecholamine metabolism is indeed
altered in coloboma mice: DA release is almost completely
disrupted in the dorsal striatum, whereas it is augmented in the
cerebral cortex (Raber et al. 1997; Jones et al. 2001) and DA
metabolite concentrations are decreased in the ventral striatum.
Likewise, NE is increased in the striatum and nucleus
accumbens of mutants (Jones et al. 2001). The experimental
depletion of NE in this model with N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine hydrochloride (DSP-4) reduces
hyperactivity and restores latent inhibition but does not ame-
liorate impulsivity (Bruno et al. 2007; Jones and Hess 2003).
This has led to the idea that the hyperlocomotor activity is
caused by a hyperactive norepinephrinergic system; however,
the finding that hyperlocomotion is not completely abolished
by NE depletion suggests that additional factors contribute to
the mutant phenotype. The deletion of SNAP25 might be
related to some of the behavioral deficits of these animals but
SNAP25 heterozygous mice (SNAP25 homozygous KO mice
are perinatally lethal) notably show no apparent phenotype
(Washbourne et al. 2002). Thus, the behavioral phenotype of
coloboma mice probably depends on the loss of genes other
than SNAP25 within the deleted region (Jeans et al. 2007;
Oliver and Davies 2009). Therefore, colobomamice have only
limited construct validity as a model of ADHD.
Among the other transgenic animals used as ADHD
models, knock-out animals for the β2-subunit of the nicotinic
acetylcholine receptor are noteworthy. They display some of
the key ADHD symptoms: inattention, lack of inhibitory
control and hyperactivity (Granon et al. 2003; Granon and
Changeux 2006). The polymorphisms of nicotinic receptor
subunits in ADHD patients and the deregulation of nicotinic
pathways in other ADHD models (i.e., DAT-KO mice; Weiss
et al. 2007) suggest that further investigations of this model as
regard to ADHD related behaviors are warranted.
Equally intriguing is the over-expression of the subunit δ
of casein kinase1 (CK1δ) in the forebrain. CK1δ is highly
expressed in the brain and regulates the phosphorylation of
DARPP-32 (dopamine and cAMP-regulated phospho-
protein MW 32 kDa), which is an important, striatally
expressed, protein phosphatase inhibitor that integrates syn-
aptic inputs from DA and glutamatergic afferents. The over-
expression of CK1δ causes a decrease in DA receptor levels
and mutant mice exhibit hyperactivity, reduced anxiety and
nesting behavior deficiencies (Zhou et al. 2010). CK1δ mice
also show paradoxical responses to psychostimulants,
displaying hypoactivity following the injection of AMPH
and MPH, indicating that CK1 activity has a profound effect
on DA signaling in vivo. Thus, despite lacking construct
validity, CK1δ over-expressing mice might have some face
and predictive validity as an ADHD model.
Another mouse model with partial construct validity is
based on the association between the gene encoding G-
protein-coupled receptor kinase-interacting protein-1 (GIT1)
and ADHD. Git1-KOmice developed by a gene trap approach
show, at younger ages, a transient hyperactivity that can be
inhibited byAMPH andMPH (Won et al. 2011). Furthermore,
these mutants display impaired learning and memory.
However, another strain of Git1-KO mice developed by ho-
mologous recombination do not demonstrate hyperactivity or
altered responses to psychostimulants during adulthood
(Schmalzigaug et al. 2009) or during development (R.T.
Premont, personal communication).
266 Cell Tissue Res (2013) 354:259–271
Recent reports have indicated that mice deficient in
Cdk5-activating cofactor p35 (Drerup et al. 2010), type 5
G protein beta subunit (Gβ5; Xie et al. 2012), or diac-
ylglycerol kinase β (Ishisaka et al. 2012) demonstrate some
phenotypes relevant to ADHD but only limited information
is available on these mutants at this time. Further detailed
investigations are necessary to validate their potential utility
as putative models of ADHD.
Concluding remarks
The opportunity to perform targeted genetic manipulations
in mice has tremendously increased our ability to evaluate
the contribution of candidate genes to the pathology of
ADHD. An ideal animal model of ADHD should display
unambiguous construct, face and predictive validity. The
major disadvantage in modeling ADHD in animals is the
absence of a commonly accepted theory on its causes and
pathogenesis. Thus, until the molecular mechanisms in-
volved in the etiology and pathology of ADHD are
deciphered, the construct validity of any animal model of
ADHD will remain limited. Under these circumstances, the
best animal models are largely based on the ability of the
model to recapitulate major endophenotypes and to demon-
strate the efficacy of the medications used in clinical prac-
tice. The growing understanding that ADHD represents a
heterogeneous disorder, with many genetic and environmen-
tal factors contributing to it, should lead to the generation of
many new animal models that might be instrumental in
modeling specific ADHD endophenotypes. Thus, each sin-
gle model has certain strengths and limitations that must be
recognized in using the model to address specific scientific
questions. Moreover, although the development of novel
transgenic animal models is critically dependent on the
identification of contributing genetic factors, the develop-
ment of reliable approaches to investigate complex behav-
iors in animals is clearly also important (Markou et al.
2009). Unfortunately, such reliability is still lacking for the
approaches used to study behavioral characteristics that are
critical for ADHD, such as attention and impulsivity, in
mice. New opportunities are emerging with the recent ability
to develop transgenic rat models, for example, through zinc-
finger nuclease technology (Geurts et al. 2010). Rats are the
preferred rodent models for cognitive research, because a
well-accepted repertoire of behavioral approaches exists to
assess complex behaviors such as impulsivity and attention.
With increasing knowledge of the etiology and pathology of
ADHD and the development of more reliable approaches to
model endophenotypes of this disorder in rodents, the trans-
lational value of these studies should increase, eventually
bringing a new generation of safer and more effective
medications.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License, which permits any use, distribution and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Adriani W, Boyer F, Gioiosa L, Macrì S, Dreyer JL, Laviola G (2009)
Increased impulsive behavior and risk proneness following
lentivirus-mediated dopamine transporter over-expression in rats’
nucleus accumbens. Neuroscience 159:47–58
Arime Y, Kasahara Y, Hall FS, Uhl GR, Sora I (2012) Cortico-
subcortical neuromodulation involved in the amelioration of
prepulse inhibition deficits in dopamine transporter knockout
mice. Neuropsychopharmacology 37:2522–2530
American Psychiatric Association (2000) Diagnostic and statistical
manual of mental disorders (DSMIV-TR), 4th edn. American
Psychiatric Association, Arlington
Bari A, Robbins TW (2011) Animal models of ADHD. Curr Top
Behav Neurosci 7:149–185
Barkley RA, Fischer M, Smallish L, Fletcher K (2004) Young adult
follow-up of hyperactive children: antisocial activities and drug
use. J Child Psychol Psychiatry 45:195–211
Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG,
Geyer MA (2004) The selective serotonin-2A receptor antagonist
M100907 reverses behavioral deficits in dopamine transporter
knockout mice. Neuropsychopharmacology 29:221–228
Beaulieu J-M, Sotnikova TD, Gainetdinov RR, Caron MG (2006)
Paradoxical striatal cellular signaling responses to psychostimulants
in hyperactive mice. J Biol Chem 281:32072–32080
Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S,
Blanco C (2012) The lifetime impact of attention deficit hyperac-
tivity disorder: results from the National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC). Psychol Med
42:875–887
Biederman J (2005) Attention-deficit/hyperactivity disorder: a selec-
tive overview. Biol Psychiatry 57:1215–1220
Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E,
Ablon S, Warburton R, Reed E (1995) Family-environment risk
factors for attention-deficit hyperactivity disorder. A test of
Rutter’s indicators of adversity. Arch Gen Psychiatry 52:464–470
Bortolozzi A, Artigas F (2003) Control of 5-hydroxytryptamine release
in the dorsal raphe nucleus by the noradrenergic system in rat
brain. Role of alpha-adrenoceptors. Neuropsychopharmacology
28:421–434
Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N,
Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A
(2010) Dysregulation of dopamine transporters via dopamine D2
autoreceptors triggers anomalous dopamine efflux associated with
attention-deficit hyperactivity disorder. J Neurosci 30:6048–6057
Bradley C (1937) The behavior of children receiving benzedrine. Am J
Psychiatry 94:577–585
Brookes KJ, Mill J, Guindalini C, Curran S, Xu X, Knight J, Chen CK,
Huang YS, Sethna V, Taylor E, Chen W, Breen G, Asherson P
(2006) A common haplotype of the dopamine transporter gene
associated with attention-deficit/hyperactivity disorder and
interacting with maternal use of alcohol during pregnancy. Arch
Gen Psychiatry 63:74–81
Brookes KJ, Hawi Z, Park J, Scott S, Gill M, Kent L (2010)
Polymorphisms of the steroid sulfatase (STS) gene are associated
with attention deficit hyperactivity disorder and influence brain
tissue mRNA expression. Am J Med Genet B Neuropsychiatr
Genet 153B:1417–1424
Cell Tissue Res (2013) 354:259–271 267
Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs
E,Weintraub BD (1995) Genetic and clinical features of 42 kindreds
with resistance to thyroid hormone. TheNational Institutes of Health
Prospective Study. Ann Intern Med 123:572–583
Bruno KJ, Freet CS, Twining RC, Egami K, Grigson PS, Hess EJ
(2007) Abnormal latent inhibition and impulsivity in coloboma
mice, a model of ADHD. Neurobiol Dis 25:206–216
Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson
ML (2001) Interactions between monoamines, glutamate, and
GABA in schizophrenia: new evidence. Annu Rev Pharmacol
Toxicol 41:237–260
Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N,
Stephens RL, Hill ER, Nottoli T, Han DD, Gu HH (2006)
Abolished cocaine reward in mice with a cocaine-insensitive
dopamine transporter. Proc Natl Acad Sci USA 103:9333–9338
Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch
SM, Niznik HB, Levey AI (1995) The dopamine transporter:
immunochemical characterization and localization in brain. J
Neurosci 15:1714–1723
Cortese S, Castellanos FX (2012) Neuroimaging of attention-deficit/
hyperactivity disorder: current neuroscience-informed perspec-
tives for clinicians. Curr Psychiatry Rep 14:568–578
Davies W, Humby T, Isles AR, Burgoyne PS, Wilkinson LS (2007) X-
monosomy effects on visuospatial attention in mice: a candidate
gene and implications for Turner syndrome and attention deficit
hyperactivity disorder. Biol Psychiatry 61:1351–1360
Davies W, Humby T, Kong W, Otter T, Burgoyne PS, Wilkinson LS
(2009) Converging pharmacological and genetic evidence indicates
a role for steroid sulfatase in attention. Biol Psychiatry 66:360–367
De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ,
Laird JM, Belmonte C, Cervero F, Hunt SP (1998) Altered
nociception, analgesia and aggression in mice lacking the receptor
for substance P. Nature 392:394–397
Dick DM, Riley B, Kendler KS (2010) Nature and nurture in neuro-
psychiatric genetics: where do we stand? Dialogues Clin Neurosci
12:7–23
Donovan DM, Miner LL, Perry MP, Revay RS, Sharpe LG,
Przedborski S, Kostic V, Philpot RM, Kirstein CL, Rothman
RB, Schindler CW, Uhl GR (1999) Cocaine reward and MPTP
toxicity: alteration by regional variant dopamine transporter
overexpression. Brain Res Mol Brain Res 73:37–49
Drerup JM, Hayashi K, Cui H, Mettlach GL, Long MA, Marvin M,
Sun X, Goldberg MS, Lutter M, Bibb JA (2010) Attention-deficit/
hyperactivity phenotype in mice lacking the cyclin-dependent
kinase 5 cofactor p35. Biol Psychiatry 68:1163–1171
Eriksen J, Jørgensen TN, Gether U (2010) Regulation of dopamine
transporter function by protein-protein interactions: new discov-
eries and methodological challenges. J Neurochem 113:27–41
Faraone SV, Khan SA (2006) Candidate gene studies of attention-deficit/
hyperactivity disorder. J Clin Psychiatry 67(Suppl 8):13–20
Faraone SV, Mick E (2010) Molecular genetics of attention deficit
hyperactivity disorder. Psychiatr Clin North Am 33:159–180
Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The world-
wide prevalence of ADHD: is it an American condition? World
Psychiatry 2:104–113
Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ,
Holmgren MA, Sklar P (2005) Molecular genetics of attention-
deficit/hyperactivity disorder. Biol Psychiatry 57:1313–1323
Fisher AS, Stewart RJ, Yan T, Hunt SP, Stanford SC (2007) Disruption
of noradrenergic transmission and the behavioural response to a
novel environment in NK1R−/− mice. Eur J Neurosci 25:1195–
1204
Forrest D, Hanebuth E, Smeyne RJ, Everds N, Stewart CL, Wehner
JM, Curran T (1996) Recessive resistance to thyroid hormone in
mice lacking thyroid hormone receptor beta: evidence for tissue-
specific modulation of receptor function. EMBO J 15:3006–3015
Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De
Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M,
Lanfumey L (2001) 5-Hydroxytryptamine (5-HT)1A autoreceptor
adaptive changes in substance P (neurokinin 1) receptor knock-
out mice mimic antidepressant-induced desensitization. J
Neurosci 21:8188–8197
Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG (1998) Role of
dopamine transporter in methamphetamine-induced neurotoxicity:
evidence frommice lacking the transporter. J Neurosci 18:4861–4869
Gainetdinov RR (2010) Strengths and limitations of genetic models of
ADHD. Atten Defic Hyperact Disord 2:21–30
Gainetdinov RR, Caron MG (2000) An animal model of attention
deficit hyperactivity disorder. Mol Med Today 6:43–44
Gainetdinov RR, Caron MG (2001) Genetics of childhood disorders:
XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model
of ADHD. J Am Acad Child Adolesc Psychiatry 40:380–382
Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron
MG (1999a) Role of serotonin in the paradoxical calming effect of
psychostimulants on hyperactivity. Science 283:397–401
Gainetdinov RR, Jones SR, Caron MG (1999b) Functional
hyperdopaminergia in dopamine transporter knock-out mice.
Biol Psychiatry 46:303–311
Gainetdinov RR, Mohn AR, Bohn LM, Caron MG (2001)
Glutamatergic modulation of hyperactivity in mice lacking the
dopamine transporter. Proc Natl Acad Sci USA 98:11047–11054
Geurts AM, Cost GJ, Rémy S, Cui X, Tesson L, Usal C, Ménoret S,
Jacob HJ, Anegon I, Buelow R (2010) Generation of gene-
specific mutated rats using zinc-finger nucleases. Methods Mol
Biol 597:211–225
Giedd JN, Blumenthal J, Molloy E, Castellanos FX (2001) Brain
imaging of attention deficit/hyperactivity disorder. Ann N Y
Acad Sci 931:33–49
Giros B, Caron MG (1993) Molecular characterization of the dopamine
transporter. Trends Pharmacol Sci 14:43–49
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996)
Hyperlocomotion and indifference to cocaine and amphetamine
in mice lacking the dopamine transporter. Nature 379:606–612
Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of
ADHD: a meta-analytic review. Hum Genet 126:51–90
Gordon I, Weizman R, Rosenne E, Rehavi M (1995) Developmental
and age-related alterations in rat brain presynaptic dopaminergic
mechanisms. Brain Res Dev Brain Res 85:225–228
Grady DL, Chi HC, Ding YC, Smith M, Wang E, Schuck S, Flodman P,
Spence MA, Swanson JM, Moyzis RK (2003) High prevalence of
rare dopamine receptor D4 alleles in children diagnosed with
attention-deficit hyperactivity disorder. Mol Psychiatry 8:536–545
Granon S, Changeux J-P (2006) Attention-deficit/hyperactivity disor-
der: a plausible mouse model? Acta Paediatr 95:645–649
Granon S, Faure P, Changeux J-P (2003) Executive and social behav-
iors under nicotinic receptor regulation. Proc Natl Acad Sci USA
100:9596–9601
Greengard P (2001) The neurobiology of dopamine signaling. Biosci
Rep 21:247–269
Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson
AJ, Weintraub BD (1993) Attention deficit-hyperactivity disorder
in people with generalized resistance to thyroid hormone. N Engl
J Med 328:997–1001
Heal DJ, Cheetham SC, Smith SL (2009) The neuropharmacology of
ADHD drugs in vivo: insights on efficacy and safety.
Neuropharmacology 57:608–618
Helms CM, Gubner NR, Wilhelm CJ, Mitchell SH, Grandy DK (2008)
D4 receptor deficiency in mice has limited effects on impulsivity
and novelty seeking. Pharmacol Biochem Behav 90:387–393
Herpfer I, Hunt SP, Stanford SC (2005) A comparison of neurokinin 1
receptor knock-out (NK1−/−) and wildtype mice: exploratory
behaviour and extracellular noradrenaline concentration in the
268 Cell Tissue Res (2013) 354:259–271
cerebral cortex of anaesthetised subjects. Neuropharmacology
48:706–719
Hess EJ, Collins KA, Copeland NG, Jenkins NA, Wilson MC (1994)
Deletion map of the coloboma (Cm) locus on mouse chromosome
2. Genomics 21:257–261
Hess EJ, Collins KA, Wilson MC (1996) Mouse model of hyperkinesis
implicates SNAP-25 in behavioral regulation. J Neurosci
16:3104–3111
Himelstein J, Newcorn JH, Halperin JM (2000) The neurobiology of
attention-deficit hyperactivity disorder. Front Biosci 5:D461–
D478
Ishisaka M, Kakefuda K, Oyagi A, Ono Y, Tsuruma K, Shimazawa
M, Kitaichi K, Hara H (2012) Diacylglycerol kinase β knock-
out mice exhibit attention-deficit behavior and an abnormal
response on methylphenidate-induced hyperactivity. PLoS One
7:e37058
Jaber M, Dumartin B, Sagné C, Haycock JW, Roubert C, Giros B,
Bloch B, Caron MG (1999) Differential regulation of tyrosine
hydroxylase in the basal ganglia of mice lacking the dopamine
transporter. Eur J Neurosci 11:3499–3511
Jeans AF, Oliver PL, JohnsonR, CapognaM, Vikman J,Molnár Z, Babbs
A, Partridge CJ, Salehi A, Bengtsson M, Eliasson L, Rorsman P,
Davies KE (2007) A dominant mutation in Snap25 causes impaired
vesicle trafficking, sensorimotor gating, and ataxia in the blind-
drunk mouse. Proc Natl Acad Sci USA 104:2431–2436
Jones MD, Hess EJ (2003) Norepinephrine regulates locomotor hyper-
activity in the mouse mutant coloboma. Pharmacol Biochem
Behav 75:209–216
Jones MD, Williams ME, Hess EJ (2001) Abnormal presynaptic cate-
cholamine regulation in a hyperactive SNAP-25-deficient mouse
mutant. Pharmacol Biochem Behav 68:669–676
Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron
MG (1998) Profound neuronal plasticity in response to inactiva-
tion of the dopamine transporter. Proc Natl Acad Sci USA
95:4029–4034
Jones SR, GainetdinovRR,CaronMG (1999)Application ofmicrodialysis
and voltammetry to assess dopamine functions in genetically altered
mice: correlation with locomotor activity. Psychopharmacology
(Berl) 147:30–32
Kalueff AV, Fox MA, Gallagher PS, Murphy DL (2007)
Hypolocomotion, anxiety and serotonin syndrome-like behavior
contribute to the complex phenotype of serotonin transporter
knockout mice. Genes Brain Behav 6:389–400
Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA,
Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S,
Weintraub B, Willingham MC, Barlow C, Cheng S (2000) Mice
with a targeted mutation in the thyroid hormone beta receptor
gene exhibit impaired growth and resistance to thyroid hormone.
Proc Natl Acad Sci USA 97:13209–13214
Kent L, Emerton J, Bhadravathi V, Weisblatt E, Pasco G, Willatt LR,
McMahon R, Yates JR (2008) X-linked ichthyosis (steroid sulfa-
tase deficiency) is associated with increased risk of attention
deficit hyperactivity disorder, autism and social communication
deficits. J Med Genet 45:519–524
Kim C-H, Waldman ID, Blakely RD, Kim K-S (2008) Functional gene
variation in the human norepinephrine transporter: association
with attention deficit hyperactivity disorder. Ann N Y Acad Sci
1129:256–260
Konrad K, Eickhoff SB (2010) Is the ADHD brain wired differently? A
review on structural and functional connectivity in attention def-
icit hyperactivity disorder. Hum Brain Mapp 31:904–916
Kostrzewa RM, Kostrzewa JP, Brown RW, Nowak P, Brus R (2008)
Dopamine receptor supersensitivity: development, mechanisms,
presentation, and clinical applicability. Neurotox Res 14:121–128
Krause J, La Fougere C, Krause K-H, Ackenheil M, Dresel SH (2005)
Influence of striatal dopamine transporter availability on the
response to methylphenidate in adult patients with ADHD. Eur
Arch Psychiatry Clin Neurosci 255:428–431
Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J,
Loland CJ, Strømgaard K, Gether U (2011) SLC6 neurotransmit-
ter transporters: structure, function, and regulation. Pharmacol
Rev 63:585–640
Lasky-Su J, Banaschewski T, Buitelaar J, Franke B, Brookes K,
Sonuga-Barke E, Ebstein R, Eisenberg J, Gill M, Manor I,
Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A,
Sergeant J, Steinhausen HC, Taylor E, Zhou K, Thompson M,
Asherson P, Faraone SV (2007) Partial replication of a DRD4
association in ADHD individuals using a statistically derived
quantitative trait for ADHD in a family-based association test.
Biol Psychiatry 62:985–990
Lee MS, Yang JW, Ko YH, Han C, Kim SH, Lee MS, Joe SH, Jung IK
(2008) Effects of methylphenidate and bupropion on DHEA-S
and cortisol plasma levels in attention-deficit hyperactivity disor-
der. Child Psychiatry Hum Dev 39:201–209
Li D, Sham PC, Owen MJ, He L (2006) Meta-analysis shows signif-
icant association between dopamine system genes and attention
deficit hyperactivity disorder (ADHD). HumMol Genet 15:2276–
2284
Ljungdahl A, Hökfelt T, Nilsson G, Goldstein M (1978) Distribution of
substance P-like immunoreactivity in the central nervous system
of the rat–II. Light microscopic localization in relation to
catecholamine-containing neurons. Neuroscience 3:945–976
Maayan R, Yoran-Hegesh R, Strous R, Nechmad A, Averbuch E,
Weizman A, Spivak B (2003) Three-month treatment course of
methylphenidate increases plasma levels of dehydroepiandroster-
one (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in
attention deficit hyperactivity disorder. Neuropsychobiology
48:111–115
Madras BK, Miller GM, Fischman AJ (2005) The dopamine transport-
er and attention-deficit/hyperactivity disorder. Biol Psychiatry
57:1397–1409
Maggi CA (1995) The mammalian tachykinin receptors. Gen
Pharmacol 26:911–944
Magner JA, Petrick P, Menezes-Ferreira MM, Stelling M, Weintraub
BD (1986) Familial generalized resistance to thyroid hormones:
report of three kindreds and correlation of patterns of affected
tissues with the binding of [125I] triiodothyronine to fibroblast
nuclei. J Endocrinol Invest 9:459–470
Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T (2009)
Removing obstacles in neuroscience drug discovery: the future path
for animal models. Neuropsychopharmacology 34:74–89
Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth
M, Sitte HH, Galli A, Blakely RD (2008) Anomalous dopamine
release associated with a human dopamine transporter coding vari-
ant. J Neurosci 28:7040–7046
McDonald MP, Wong R, Goldstein G, Weintraub B, Cheng SY,
Crawley JN (1998) Hyperactivity and learning deficits in trans-
genic mice bearing a human mutant thyroid hormone beta1 re-
ceptor gene. Learn Mem 5:289–301
McLean S, Lowe III JA (1994) Agonist and antagonist receptor bind-
ing. In: Buck SH (ed) The tachykinin receptors.Humana, Totowa,
N.J., pp 67–99
Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S (2002a) Case–
control study of attention-deficit hyperactivity disorder and ma-
ternal smoking, alcohol use, and drug use during pregnancy. J Am
Acad Child Adolesc Psychiatry 41:378–385
Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV (2002b)
Impact of low birth weight on attention-deficit hyperactivity dis-
order. J Dev Behav Pediatr 23:16–22
Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh
K, Birney E, Rogers J, Abril JF et al (2002) Initial sequencing and
comparative analysis of the mouse genome. Nature 420:520–562
Cell Tissue Res (2013) 354:259–271 269
Murtra P, Sheasby AM, Hunt SP, De Felipe C (2000) Rewarding
effects of opiates are absent in mice lacking the receptor for
substance P. Nature 405:180–183
Napolitano F, Bonito-Oliva A, Federici M, Carta M, Errico F, Magara
S, Martella G, Nisticò R, Centonze D, Pisani A, Gu HH, Mercuri
NB, Usiello A (2010) Role of aberrant striatal dopamine D1
receptor/cAMP/protein kinase A/DARPP32 signaling in the par-
adoxical calming effect of amphetamine. J Neurosci 30:11043–
11056
Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1996)
The dopamine transporter is localized to dendritic and axonal
plasma membranes of nigrostriatal dopaminergic neurons. J
Neurosci 16:436–447
Oliver PL, Davies KE (2009) Interaction between environmental and
genetic factors modulates schizophrenic endophenotypes in the
Snap-25 mouse mutant blind-drunk. Hum Mol Genet 18:4576–
4589
Patel AP, Cerruti C, Vaughan RA, Kuhar MJ (1994) Developmentally
regulated glycosylation of dopamine transporter. Brain Res Dev
Brain Res 83:53–58
Pifl C, Giros B, Caron MG (1996) The dopamine transporter. The
cloned target site of Parkinsonism-inducing toxins and of drugs
of abuse. Adv Neurol 69:235–238
Pliszka SR (2005) The neuropsychopharmacology of attention-deficit/
hyperactivity disorder. Biol Psychiatry 57:1385–1390
Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA (2007)
The worldwide prevalence of ADHD: a systematic review and
metaregression analysis. Am J Psychiatry 164:942–948
Purper-Ouakil D, Ramoz N, Lepagnol-Bestel A-M, Gorwood P,
Simonneau M (2011) Neurobiology of attention deficit/hyperac-
tivity disorder. Pediatr Res 69:69R–76R
Raber J, Mehta PP, Kreifeldt M, Parsons LH, Weiss F, Bloom FE,
Wilson MC (1997) Coloboma hyperactive mutant mice exhibit
regional and transmitter-specific deficits in neurotransmission. J
Neurochem 68:176–186
Reddy DS (2010) Neurosteroids: endogenous role in the human brain
and therapeutic potentials. Prog Brain Res 186:113–137
Ribeiro-da-Silva A, Hökfelt T (2000) Neuroanatomical localisation of
Substance P in the CNS and sensory neurons. Neuropeptides
34:256–271
Rubia K, Cubillo A, Smith AB, Woolley J, Heyman I, Brammer MJ
(2010) Disorder-specific dysfunction in right inferior prefrontal
cortex during two inhibition tasks in boys with attention-deficit
hyperactivity disorder compared to boys with obsessive-
compulsive disorder. Hum Brain Mapp 31:287–299
Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski
G, Zhang G, Fang Y, Larson JL, McDougall JA, Chester JA, Saez
C, Pugsley TA, Gershanik O, Low MJ, Grandy DK (1997) Mice
lacking dopamine D4 receptors are supersensitive to ethanol,
cocaine, and methamphetamine. Cell 90:991–1001
Russell VA (2011) Overview of animal models of attention deficit
hyperactivity disorder (ADHD). Curr Protoc Neurosci 9:Unit9.35
Russell VA, Sagvolden T, Johansen EB (2005) Animal models of
attention-deficit hyperactivity disorder. Behav Brain Funct 1:9
Sagvolden T, Johansen EB (2012) Rat models of ADHD. Curr Top
Behav Neurosci 9:301–315
Sagvolden T, Johansen EB, Wøien G, Walaas SI, Storm-Mathisen J,
Bergersen LH, Hvalby O, Jensen V, Aase H, Russell VA, Killeen
PR, Dasbanerjee T, Middleton FA, Faraone SV (2009) The spon-
taneously hypertensive rat model of ADHD—the importance of
selecting the appropriate reference strain. Neuropharmacology
57:619–626
Sakrikar D, Mazei-Robison MS, Mergy MA, Richtand NW, Han Q,
Hamilton PJ, Bowton E, Galli A, Veenstra-Vanderweele J, Gill M,
Blakely RD (2012) Attention deficit/hyperactivity disorder-
derived coding variation in the dopamine transporter disrupts
microdomain targeting and trafficking regulation. J Neurosci
32:5385–5397
Salahpour A, Medvedev IO, Beaulieu J-M, Gainetdinov RR, Caron
MG (2007) Local knockdown of genes in the brain using small
interfering RNA: a phenotypic comparison with knockout ani-
mals. Biol Psychiatry 61:65–69
Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD,
Holmstrand E, Ghisi V, Nicholls PJ, Wong L, Murphy K,
Sesack SR, Wightman RM, Gainetdinov RR, Caron MG (2008)
Increased amphetamine-induced hyperactivity and reward in mice
overexpressing the dopamine transporter. Proc Natl Acad Sci
USA 105:4405–4410
Schmalzigaug R, Rodriguiz RM, Bonner PE, Davidson CE, Wetsel
WC, Premont RT (2009) Impaired fear response in mice lacking
GIT1. Neurosci Lett 458:79–83
Searle AG (1966) New mutants. II. Coloboma. Mouse News Lett
35:27
Siesser WB, Cheng S, McDonald MP (2005) Hyperactivity, impaired
learning on a vigilance task, and a differential response to methyl-
phenidate in the TRbetaPV knock-in mouse. Psychopharmacology
(Berl) 181:653–663
Siesser WB, Zhao J, Miller LR, Cheng S-Y, McDonald MP (2006)
Transgenic mice expressing a human mutant beta1 thyroid recep-
tor are hyperactive, impulsive, and inattentive. Genes Brain
Behav 5:282–297
Sinopoli KJ, Schachar R, Dennis M (2011) Traumatic brain injury and
secondary attention-deficit/hyperactivity disorder in children and
adolescents: the effect of reward on inhibitory control. J Clin Exp
Neuropsychol 33:805–819
Smithies O (1993) Animal models of human genetic diseases. Trends
Genet 9:112–116
Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG,
Gainetdinov RR (2005) Dopamine-independent locomotor ac-
tions of amphetamines in a novel acute mouse model of
Parkinson disease. PLoS Biol 3:e271
Spencer TJ, Biederman J, Faraone SV, Madras BK, Bonab AA,
Dougherty DD, Batchelder H, Clarke A, Fischman AJ (2012)
Functional genomics of attention-deficit/hyperactivity disorder
(ADHD) risk alleles on dopamine transporter binding in ADHD
and healthy control subjects. Biol Psychiatry. doi:10.1016/
j.biopsych.2012.11.010
Stergiakouli E, Langley K, Williams H, Walters J, Williams NM, Suren
S, Giegling I, Wilkinson LS, Owen MJ, O'Donovan MC, Rujescu
D, Thapar A, Davies W (2011) Steroid sulfatase is a potential
modifier of cognition in attention deficit hyperactivity disorder.
Genes Brain Behav 10:334–344
Strous RD, Spivak B, Yoran-Hegesh R, Maayan R, Averbuch E, Kotler
M, Mester R, Weizman A (2001) Analysis of neurosteroid levels in
attention deficit hyperactivity disorder. Int J Neuropsychopharmacol
4:259–264
Thomsen M, Han DD, Gu HH, Caine SB (2009) Lack of cocaine self-
administration in mice expressing a cocaine-insensitive dopamine
transporter. J Pharmacol Exp Ther 331:204–211
Tilley MR, Gu HH (2008a) The effects of methylphenidate on knockin
mice with a methylphenidate-resistant dopamine transporter. J
Pharmacol Exp Ther 327:554–560
Tilley MR, Gu HH (2008b) Dopamine transporter inhibition is required
for cocaine-induced stereotypy. Neuroreport 19:1137–1140
Tilley MR, Cagniard B, Zhuang X, Han DD, Tiao N, Gu HH (2007)
Cocaine reward and locomotion stimulation in mice with reduced
dopamine transporter expression. BMC Neurosci 8:42
Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane
monoamine transporters: structure, regulation and function. Nat
Rev Neurosci 4:13–25
Trent S, Cassano T, Bedse G, Ojarikre OA, Humby T, Davies W
(2012a) Altered serotonergic function may partially account for
270 Cell Tissue Res (2013) 354:259–271
behavioral endophenotypes in steroid sulfatase-deficient mice.
Neuropsychopharmacology 37:1267–1274
Trent S, Dennehy A, Richardson H, Ojarikre OA, Burgoyne PS,
Humby T, Davies W (2012b) Steroid sulfatase-deficient mice
exhibit endophenotypes relevant to attention deficit hyperactivity
disorder. Psychoneuroendocrinology 37:221–229
Trinh JV, Nehrenberg DL, Jacobsen JPR, Caron MG, Wetsel WC
(2003) Differential psychostimulant-induced activation of neural
circuits in dopamine transporter knockout and wild type mice.
Neuroscience 118:297–310
Valera EM, Faraone SV, Murray KE, Seidman LJ (2007) Meta-analysis
of structural imaging findings in attention-deficit/hyperactivity
disorder. Biol Psychiatry 61:1361–1369
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002)
Mechanism of action of methylphenidate: insights from PET
imaging studies. J Atten Disord 6 (Suppl 1):S31–S43
Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV,
Logan J, Wong C, Ma Y, Swanson JM, Schulz K, Pradhan K
(2007) Brain dopamine transporter levels in treatment and drug
naive adults with ADHD. Neuroimage 34:1182–1190
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F,
Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson
JM (2009a) Evaluating dopamine reward pathway in ADHD:
clinical implications. JAMA 302:1084–1091
Volkow ND, Fowler JS, Logan J, Alexoff D, ZhuW, Telang F, Wang GJ,
Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D,
King P, Shea C, Xu Y, Muench L, Apelskog-Torres K (2009b)
Effects of modafinil on dopamine and dopamine transporters in
the male human brain: clinical implications. JAMA 301:1148–1154
Washbourne P, Thompson PM, Carta M, Costa ET, Mathews JR,
Lopez-Benditó G, Molnár Z, Becher MW, Valenzuela CF,
Partridge LD, Wilson MC (2002) Genetic ablation of the t-
SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis.
Nat Neurosci 5:19–26
Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J,
Giros B, Martres MP (2007) Functional alterations of nicotinic
neurotransmission in dopamine transporter knock-out mice.
Neuropharmacology 52:1496–1508
Willcutt EG (2012) The prevalence of DSM-IV attention-deficit/hyper-
activity disorder: a meta-analytic review. Neurotherapeutics
9:490–499
Wilson MC (2000) Coloboma mouse mutant as an animal model of
hyperkinesis and attention deficit hyperactivity disorder. Neurosci
Biobehav Rev 24:51–57
Won H, Mah W, Kim E, Kim JW, Hahm EK, Kim MH, Cho S, Kim J,
Jang H, Cho SC, Kim BN, Shin MS, Seo J, Jeong J, Choi SY, Kim
D, Kang C, Kim E (2011) GIT1 is associated with ADHD in
humans and ADHD-like behaviors in mice. Nat Med 17:566–572
Wong P, Chang CC, Marx CE, Caron MG, Wetsel WC, Zhang X
(2012) Pregnenolone rescues schizophrenia-like behavior in do-
pamine transporter knockout mice. PLoS One 7:e51455
Wu J, Xiao H, Sun H, Zou L, Zhu L-Q (2012) Role of dopamine
receptors in ADHD: a systematic meta-analysis. Mol Neurobiol
45:605–620
Xie K, Ge S, Collins VE, Haynes CL, Renner KJ, Meisel RL, Lujan R,
Martemyanov KA (2012) Gβ5-RGS complexes are gatekeepers
of hyperactivity involved in control of multiple neurotransmitter
systems. Psychopharmacology (Berl) 219:823–834
Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW,
Wang YM, Caron MG (2000) Mice lacking the norepinephrine
transporter are supersensitive to psychostimulants. Nat Neurosci
3:465–471
Xu TX, Sotnikova TD, Liang C, Zhang J, Jung JU, Spealman RD,
Gainetdinov RR, Yao WD (2009) Hyperdopaminergic tone erodes
prefrontal long-term potential via a D2 receptor-operated protein
phosphatase gate. J Neurosci 29:14086–14099
Yadid G, Sudai E, Maayan R, Gispan I, Weizman A (2010) The role of
dehydroepiandrosterone (DHEA) in drug-seeking behavior.
Neurosci Biobehav Rev 35:303–314
Yamashita M, Sakakibara Y, Hall FS, Numachi Y, Yoshida S,
Kobayashi H, Uchiumi O, Uhl GR, Kasahara Y, Sora I (2013)
Impaired cliff avoidance reaction in dopamine transporter knock-
out mice. Psychopharmacology (Berl). doi:10.1007/s00213-013-
3009-9
Yan TC, Hunt SP, Stanford SC (2009) Behavioural and neurochemical
abnormalities in mice lacking functional tachykinin-1 (NK1) re-
ceptors: a model of attention deficit hyperactivity disorder.
Neuropharmacology 57:627–635
Yan TC, McQuillin A, Thapar A, Asherson P, Hunt SP, Stanford SC,
Gurling H (2010) NK1 (TACR1) receptor gene “knockout”
mouse phenotype predicts genetic association with ADHD. J
Psychopharmacol 24:27–38
Yan TC, Dudley JA, Weir RK, Grabowska EM, Peña-Oliver Y, Ripley
TL, Hunt SP, Stephens DN, Stanford SC (2011) Performance
deficits of NK1 receptor knockout mice in the 5-choice serial
reaction-time task: effects of d-amphetamine, stress and time of
day. PLoS One 6:e17586
Yang L, Wang Y-F, Li J, Faraone SV (2004) Association of norepi-
nephrine transporter gene with methylphenidate response. J Am
Acad Child Adolesc Psychiatry 43:1154–1158
Zhou M, Rebholz H, Brocia C, Warner-Schmidt JL, Fienberg AA, Nairn
AC, Greengard P, Flajolet M (2010) Forebrain overexpression of
CK1delta leads to down-regulation of dopamine receptors and al-
tered locomotor activity reminiscent of ADHD. Proc Natl Acad Sci
USA 107:4401–4406
Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron
MG, Hen R (2001) Hyperactivity and impaired response habitu-
ation in hyperdopaminergic mice. Proc Natl Acad Sci USA
98:1982–1987
Zoli M, Jansson A, Syková E, Agnati LF, Fuxe K (1999) Volume trans-
mission in the CNS and its relevance for neuropsychopharmacology.
Trends Pharmacol Sci 20:142–150
Cell Tissue Res (2013) 354:259–271 271
